Rate of Second Primary Lung Cancers With Lobar vs Sublobar Resection of T1aN0 NSCLC
... with both sublobar and lobar resections for T1aN0 non–small cell lung cancer (NSCLC).
Thomas E. Stinchcombe, MD
Study Details
In ...
... with both sublobar and lobar resections for T1aN0 non–small cell lung cancer (NSCLC).
Thomas E. Stinchcombe, MD
Study Details
In ...
Dr. Sun turned to targeted therapies for lung cancer and focused on the third-generation EGFR tyrosine kinase inhibitor osimertinib. ...
The study was published in Cancer Discovery and funded by Cancer Research UK (CRUK) and Bristol Myers Squibb.
Non-small cell lung ...
... alterations were calculated for a total of 3,854 patients with non-small cell lung cancer (n = 61 1,753), breast carcinoma (n = 835 ...
... 453 patients from Chinese centers with resectable stage II to IIIA NSCLC of squamous or nonsquamous histology, with no known EGFR ...
... than neoadjuvant chemotherapy in patients with non–small cell lung cancer (NSCLC).
Study Details
A search of published studies ...
Exposure to Agent Orange is associated with increased recurrence after surgical treatment of stage I non–small cell lung cancer ...
Impact of travel distance on receipt of indicated adjuvant therapy in resected non–small cell lung cancer ...
Annual Conference 2024 in Tampa, Florida titled “What’s New in NSCLC Therapies? Key Takeaways for Your Pharmacy Practice.” Lewis discusses ...
... in the United States
Sexual Health Assessment in Women With Lung Cancer Study: Sexual Health Assessment in Women With Lung Cancer
EGFR </em ...